Artículos de revistas sobre el tema "Dual inhibitors"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Dual inhibitors".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Sipos, Ádám, Eszter Szennyes, Nikolett Éva Hajnal, Sándor Kun, Katalin E. Szabó, Karen Uray, László Somsák, Tibor Docsa y Éva Bokor. "Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors". Pharmaceuticals 14, n.º 4 (15 de abril de 2021): 364. http://dx.doi.org/10.3390/ph14040364.
Texto completoGesinski, Dayna y Sonali Kurup. "Abstract 5337: Design, synthesis and evaluation of dual-targeted mEGFR and AURK inhibitors as anticancer agents". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 5337. http://dx.doi.org/10.1158/1538-7445.am2023-5337.
Texto completoKim, Min-Jeong, Sarita Pandit y Jun-Goo Jee. "Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments". Pharmaceuticals 15, n.º 2 (16 de febrero de 2022): 236. http://dx.doi.org/10.3390/ph15020236.
Texto completoBošković, Jelena, Vladimir Dobričić, Marija Mihajlović, Jelena Kotur-Stevuljević y Olivera Čudina. "Synthesis, Evaluation of Enzyme Inhibition and Redox Properties of Potential Dual COX-2 and 5-LOX Inhibitors". Pharmaceuticals 16, n.º 4 (6 de abril de 2023): 549. http://dx.doi.org/10.3390/ph16040549.
Texto completoWang, Q. May, Robert B. Johnson, Louis N. Jungheim, Jeffrey D. Cohen y Elcira C. Villarreal. "Dual Inhibition of Human Rhinovirus 2A and 3C Proteases by Homophthalimides". Antimicrobial Agents and Chemotherapy 42, n.º 4 (1 de abril de 1998): 916–20. http://dx.doi.org/10.1128/aac.42.4.916.
Texto completoLu, Haiying, Lan Bai, Yanping Zhou, Yongping Lu, Zhongliang Jiang y Jianyou Shi. "Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor". Current Topics in Medicinal Chemistry 19, n.º 12 (30 de julio de 2019): 1041–50. http://dx.doi.org/10.2174/1568026619666190603092407.
Texto completoWen, Hui, Wen Qin, Guangzhong Yang y Yanshen Guo. "Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors". Molecules 24, n.º 3 (30 de enero de 2019): 497. http://dx.doi.org/10.3390/molecules24030497.
Texto completoVest, Rebekah S., Kurtis D. Davies, Heather O'Leary, J. David Port y K. Ulrich Bayer. "Dual Mechanism of a Natural CaMKII Inhibitor". Molecular Biology of the Cell 18, n.º 12 (diciembre de 2007): 5024–33. http://dx.doi.org/10.1091/mbc.e07-02-0185.
Texto completoLambert, Que T., Stuart W. Ember, Muhammad Ayaz, Harshani R. Lawrence, Norbert Berndt, Steven Gunawan, Nicholas J. Lawrence, Ernst Schönbrunn y Gary W. Reuther. "Single Molecule Dual JAK2-BET Inhibition As an MPN Therapeutic". Blood 126, n.º 23 (3 de diciembre de 2015): 2826. http://dx.doi.org/10.1182/blood.v126.23.2826.2826.
Texto completoDyer, Richard D. y David T. Connor. "Dual Inhibitors Of Prostaglandin And Leukotriene Biosynthesis". Current Pharmaceutical Design 3, n.º 5 (1997): 463–72. http://dx.doi.org/10.2174/138161280305221010095741.
Texto completoOmidkhah, Negar y Razieh Ghodsi. "NO-HDAC dual inhibitors". European Journal of Medicinal Chemistry 227 (enero de 2022): 113934. http://dx.doi.org/10.1016/j.ejmech.2021.113934.
Texto completoDong, Hang, Hao Yin, Chunlong Zhao, Jiangying Cao, Wenfang Xu y Yingjie Zhang. "Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors". Molecules 24, n.º 13 (29 de junio de 2019): 2407. http://dx.doi.org/10.3390/molecules24132407.
Texto completoRogers, Brianne, Nicholas Rohde, Justin Mikitaroff, Joshua Matson, Samantha Satawa, Felix Amissah y Sonali Kurup. "Abstract 5339: 4-Amino-N-phenylbenzamides as dual-targeted mEGFR and AURK inhibitors and anticancer agents". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 5339. http://dx.doi.org/10.1158/1538-7445.am2023-5339.
Texto completoKUMAR, Priyadarsini y Donal A. WALSH. "A dual-specificity isoform of the protein kinase inhibitor PKI produced by alternate gene splicing". Biochemical Journal 362, n.º 3 (8 de marzo de 2002): 533–37. http://dx.doi.org/10.1042/bj3620533.
Texto completoMao, Beibei, Qi Zhang, Li Ma, Dong-Sheng Zhao, Pan Zhao y Peizheng Yan. "Overview of Research into mTOR Inhibitors". Molecules 27, n.º 16 (19 de agosto de 2022): 5295. http://dx.doi.org/10.3390/molecules27165295.
Texto completoSun, Xuefeng, Ningning Fan, Weisi Xu, Yixing Sun, Xin Xie, Ying Guo, Liying Ma, Junyi Liu y Xiaowei Wang. "Design, synthesis and biological evaluation of caffeoyl benzanilides as dual inhibitors of HIV integrase and CCR5". MedChemComm 7, n.º 10 (2016): 2028–32. http://dx.doi.org/10.1039/c6md00311g.
Texto completoCheng, Haoyang, Yanruisheng Shao y Yan Zhang. "Research Progress of PARP-1 Related Dual Target Inhibitors". Highlights in Science, Engineering and Technology 6 (27 de julio de 2022): 111–20. http://dx.doi.org/10.54097/hset.v6i.952.
Texto completoHou, Xiaodan, Honghua Yan, Xin Zhang, Weidong Qian, Dong Chen, Zhihua Ren y Youzhi Tong. "Abstract 6509: GT0486, a novel mTORC1/2 dual inhibitor, exhibits synergistic antitumor efficacy in combination with BTK inhibitors". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 6509. http://dx.doi.org/10.1158/1538-7445.am2024-6509.
Texto completoWeisberg, Ellen, Lolita Banerji, Renee D. Wright, Rosemary Barrett, Arghya Ray, Daisy Moreno, Laurence Catley et al. "Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells". Blood 111, n.º 7 (1 de abril de 2008): 3723–34. http://dx.doi.org/10.1182/blood-2007-09-114454.
Texto completoUpadhayaya, Ram S., Raghava Reddy Kethiri, Avanish Vellanki, Jeff Lightfoot, Andrea Local y William G. Rice. "Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies". Blood 128, n.º 22 (2 de diciembre de 2016): 5212. http://dx.doi.org/10.1182/blood.v128.22.5212.5212.
Texto completoWong, Jacky, Robert Welschinger, Rana Baraz, Jocelyn Weiss, Ken Bradstock y Linda J. Bendall. "Comparision of Dual PI-3K/mTOR Inhibitors with mTOR Inhibitors Using a Pre-Clinical Model of Acute Lymphoblastic Leukemia". Blood 116, n.º 21 (19 de noviembre de 2010): 3258. http://dx.doi.org/10.1182/blood.v116.21.3258.3258.
Texto completoWong, Jacky, Robert Welschinger, Rana Baraz, Kenneth Francis Bradstock y Linda J. Bendall. "Application of Dual PI-3K/mTOR Inhibitors Is Not Always Superior to Inhibition of mTOR Alone.",. Blood 118, n.º 21 (18 de noviembre de 2011): 3575. http://dx.doi.org/10.1182/blood.v118.21.3575.3575.
Texto completoMin, Jian, Jerome C. Nwachukwu, Charles K. Min, Jacqline W. Njeri, Sathish Srinivasan, Erumbi S. Rangarajan, Charles C. Nettles et al. "Dual-mechanism estrogen receptor inhibitors". Proceedings of the National Academy of Sciences 118, n.º 35 (27 de agosto de 2021): e2101657118. http://dx.doi.org/10.1073/pnas.2101657118.
Texto completovan Gijn, R., R. R. H. Lendfers, J. H. M. Schellens, A. Bult y J. H. Beijnen. "Dual topoisomerase I/II inhibitors". Journal of Oncology Pharmacy Practice 6, n.º 3 (1 de marzo de 2000): 92–108. http://dx.doi.org/10.1191/107815500701563317.
Texto completoKhan, Anwar A. y Guang-Wen Zeng. "Dual Action of Respiratory Inhibitors". Plant Physiology 77, n.º 4 (1 de abril de 1985): 817–23. http://dx.doi.org/10.1104/pp.77.4.817.
Texto completovan Gijn, R., RRH Lendfers, JHM Schellens, A. Bult y JH Beijnen. "Dual topoisomerase I/II inhibitors". Journal of Oncology Pharmacy Practice 6, n.º 3 (septiembre de 2000): 92–108. http://dx.doi.org/10.1177/107815520000600303.
Texto completoWoo, L. W. Lawrence, Christian Bubert, Oliver B. Sutcliffe, Andrew Smith, Surinder K. Chander, Mary F. Mahon, Atul Purohit, Michael J. Reed y Barry V. L. Potter. "Dual Aromatase−Steroid Sulfatase Inhibitors". Journal of Medicinal Chemistry 50, n.º 15 (julio de 2007): 3540–60. http://dx.doi.org/10.1021/jm061462b.
Texto completoCai, Chao-Yun, Qiu-Xu Teng, Megumi Murakami, Suresh V. Ambudkar, Zhe-Sheng Chen y Vijaya L. Korlipara. "Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability". Biomolecules 13, n.º 2 (30 de enero de 2023): 253. http://dx.doi.org/10.3390/biom13020253.
Texto completoKozak, Wieslaw, Inez Archuleta, Kimberly P. Mayfield, Anna Kozak, Karin Rudolph y Matthew J. Kluger. "Inhibitors of alternative pathways of arachidonate metabolism differentially affect fever in mice". American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 275, n.º 4 (1 de octubre de 1998): R1031—R1040. http://dx.doi.org/10.1152/ajpregu.1998.275.4.r1031.
Texto completoKurup, Sonali, Gabe Carpenter, Samantha Satawa, Felix Amissah, Erika Lisabeth, Matthew Giletto y Edmund Ellsworth. "Abstract 4474: Novel analogs of 4-substituted pyrrolo[2,3-d]pyrimidines as dual-targeted mEGFR/AURKA inhibitors for lung cancer". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 4474. http://dx.doi.org/10.1158/1538-7445.am2024-4474.
Texto completoWu, Yichao, Weichen Dai, Xin Chen, Aixin Geng, Yadong Chen, Tao Lu y Yong Zhu. "Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors". RSC Advances 7, n.º 82 (2017): 52180–86. http://dx.doi.org/10.1039/c7ra08835c.
Texto completoChen, Xin, Shuang Zhao, Yichao Wu, Yadong Chen, Tao Lu y Yong Zhu. "Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors". RSC Advances 6, n.º 105 (2016): 103178–84. http://dx.doi.org/10.1039/c6ra21271a.
Texto completoEstrada, Filipe G. A., Silvia Miccoli, Natália Aniceto, Alfonso T. Garcia-Sosa y Rita C. Guedes. "Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma". Molecules 26, n.º 18 (14 de septiembre de 2021): 5574. http://dx.doi.org/10.3390/molecules26185574.
Texto completoGuenther, Andreas, Renate Burger, Wolfram Klapper, Matthias Staudinger, Kathrin Richter, Tanja Ahrens y Martin Gramatzki. "Inhibitors of Mtor and PI3K Synergistically Block Plasmacytoma Cell Growth". Blood 118, n.º 21 (18 de noviembre de 2011): 2903. http://dx.doi.org/10.1182/blood.v118.21.2903.2903.
Texto completoKramer, Victor G., Susan M. Schader, Maureen Oliveira, Susan P. Colby-Germinario, Daniel A. Donahue, Diane N. Singhroy, Randy Tressler, Richard D. Sloan y Mark A. Wainberg. "Maraviroc and Other HIV-1 Entry Inhibitors Exhibit a Class-Specific Redistribution Effect That Results in Increased Extracellular Viral Load". Antimicrobial Agents and Chemotherapy 56, n.º 8 (21 de mayo de 2012): 4154–60. http://dx.doi.org/10.1128/aac.00409-12.
Texto completoLeufven, Eva y Øystein Bruserud. "Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments". Current Medicinal Chemistry 26, n.º 28 (25 de octubre de 2019): 5244–61. http://dx.doi.org/10.2174/0929867326666190325095853.
Texto completoBao, Le-Quang, Daniel Baecker, Do Thi Mai Dung, Nguyen Phuong Nhung, Nguyen Thi Thuan, Phuong Linh Nguyen, Phan Thi Phuong Dung et al. "Development of Activity Rules and Chemical Fragment Design for In Silico Discovery of AChE and BACE1 Dual Inhibitors against Alzheimer’s Disease". Molecules 28, n.º 8 (20 de abril de 2023): 3588. http://dx.doi.org/10.3390/molecules28083588.
Texto completoSpinaci, Andrea, Michela Buccioni, Daniela Catarzi, Chang Cui, Vittoria Colotta, Diego Dal Ben, Eleonora Cescon et al. "“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies". Pharmaceuticals 16, n.º 2 (23 de enero de 2023): 167. http://dx.doi.org/10.3390/ph16020167.
Texto completoZhang, Lingzhi, Qiurong Ju, Jinjin Sun, Lei Huang, Shiqi Wu, Shuping Wang, Yin Li, Zhe Guan, Qihua Zhu y Yungen Xu. "Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy". Molecules 25, n.º 23 (3 de diciembre de 2020): 5693. http://dx.doi.org/10.3390/molecules25235693.
Texto completoBachmann, Luisa M., Maria Hanl, Felix Feller, Laura Sinatra, Andrea Schöler, Jens Pietzsch, Markus Laube y Finn K. Hansen. "Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors". Molecules 28, n.º 3 (20 de enero de 2023): 1061. http://dx.doi.org/10.3390/molecules28031061.
Texto completoŢînţaş, Mihaela-Liliana, Ludovic Peauger, Florent Alix, Cyril Papamicaël, Thierry Besson, Jana Sopková-de Oliveira Sopková-de Oliveira Santos, Vincent Gembus y Vincent Levacher. "Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core". Molecules 28, n.º 1 (21 de diciembre de 2022): 36. http://dx.doi.org/10.3390/molecules28010036.
Texto completoMolins, Joaquim Bellmunt, Lillian Werner, Marta Guix, Elizabeth Ann Guancial, Fabio Augusto Barros Schutz, Robert O'Brien, Edward C. Stack et al. "PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?" Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 4582. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4582.
Texto completoWoo, L. W. Lawrence, Christian Bubert, Atul Purohit y Barry V. L. Potter. "Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity". ACS Medicinal Chemistry Letters 2, n.º 3 (29 de diciembre de 2010): 243–47. http://dx.doi.org/10.1021/ml100273k.
Texto completoJończyk, Jakub, Justyna Godyń, Ewelina Stawarska, Beata Morak-Młodawska, Małgorzata Jeleń, Krystian Pluta y Barbara Malawska. "Dual Action of Dipyridothiazine and Quinobenzothiazine Derivatives—Anticancer and Cholinesterase-Inhibiting Activity". Molecules 25, n.º 11 (3 de junio de 2020): 2604. http://dx.doi.org/10.3390/molecules25112604.
Texto completoMahnashi, Mater H., Sravanthi Avunoori, Sanjay Gopi, Ibrahim Ahmed Shaikh, Ahmed Saif, Farkad Bantun, Hani Saleh Faidah et al. "Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase". PLOS ONE 19, n.º 5 (13 de mayo de 2024): e0303173. http://dx.doi.org/10.1371/journal.pone.0303173.
Texto completoKwon, Young-Ju, Dong Young Kim, Uk-Il Kim, Xue Meng, Ho Kyun Lee, Hyung Tae Bang, Jae-Sung Kim y Kyungjin Kim. "Abstract 491: Tankyrase-selective inhibitor STP1002 reverses resistance to MEK inhibitors in colorectal cancer with KRAS mutations". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 491. http://dx.doi.org/10.1158/1538-7445.am2023-491.
Texto completoAl-Wahaibi, Lamya H., Hesham A. Abou-Zied, Mohamed Hisham, Eman A. M. Beshr, Bahaa G. M. Youssif, Stefan Bräse, Alaa M. Hayallah y Mohamed Abdel-Aziz. "Design, Synthesis, and Biological Evaluation of Novel 3-Cyanopyridone/Pyrazoline Hybrids as Potential Apoptotic Antiproliferative Agents Targeting EGFR/BRAFV600E Inhibitory Pathways". Molecules 28, n.º 18 (12 de septiembre de 2023): 6586. http://dx.doi.org/10.3390/molecules28186586.
Texto completoTanabe, Kenji. "Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors". International Journal of Molecular Sciences 18, n.º 12 (23 de noviembre de 2017): 2508. http://dx.doi.org/10.3390/ijms18122508.
Texto completoTabrizchi, Reza. "Dual ACE and Neutral Endopeptidase Inhibitors". Drugs 63, n.º 20 (2003): 2185–202. http://dx.doi.org/10.2165/00003495-200363200-00003.
Texto completoOmidkhah, Negar, Farzin Hadizadeh y Razieh Ghodsi. "Dual HDAC/BRD4 inhibitors against cancer". Medicinal Chemistry Research 30, n.º 10 (14 de agosto de 2021): 1822–36. http://dx.doi.org/10.1007/s00044-021-02776-9.
Texto completo